Head-to-head evidence
3BNC117 vs Lotivibart
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV envelope · full HIV pipeline
3BNC117
Developed by Frontier Biotechnologies and partners
NCT03041012 · Phase 2 · completed
The trial randomly assigned 60 participants to four groups, including standard antiretroviral therapy alone and combinations containing 3BNC117, but treatment was not blinded. Its primary outcomes were virologic and reservoir measures rather than hard clinical outcomes, and the registry provides no results showing whether any primary comparison was met.
Next expected readout: December 2026 · NCT05300035 (registry estimate)
Lotivibart
Developed by ViiV Healthcare
NCT04871113 · Phase 2 · completed
Participants were randomized among dose cohorts, but the study was open-label, had no placebo or active comparator during monotherapy, and included only 6 to 16 participants per cohort. The primary endpoint was the surrogate measure of maximum decline in HIV-1 RNA and was reported descriptively without a formal comparative efficacy test, so the findings do not establish comparative treatment benefit.
Next expected readout: January 2027 · NCT07053384 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: 3BNC117's landscape · Lotivibart's landscape